Exposure-response of olaratumab for survival outcomes and safety when combined with doxorubicin in soft tissue sarcoma (STS) patients

Authors :: Damien M. Cronier
Ilaria Conti
William D. Tap
R.D. Nichols
Robert Ilaria
John R. Baldwin
Gary Mo
Robin L. Jones
Source :: Annals of Oncology. 27:vi485
Publication Year :: 2016
Publisher :: Elsevier BV, 2016.

Subjects :: Oncology
medicine.medical_specialty
business.industry
Soft tissue sarcoma
Hematology
medicine.disease
Surgery
Internal medicine
medicine
Doxorubicin
business
Exposure response
Olaratumab
medicine.drug

Full Text Access

Tools